Home | To evaluate the immunogenicity and safety of SOBERANA® 02 and SOBERANA® Plus as booster of immunity against the omicrom variant of SARS-CoV-2, in adult subjects

The revisions let you track differences between multiple versions of a post.

To edit, publish or delete one of the revisions below, click on its saved date.

Published clinical_trials To evaluate the immunogenicity and safety of SOBERANA® 02 and SOBERANA® Plus as booster of immunity against the omicrom variant of SARS-CoV-2, in adult subjects has 2 revisions.
RevisionStatus
Saved 19/12/2025 - 10:33pm by Gladys
current revision (published)
Saved 19/05/2023 - 2:06pm by Gladys
archived